Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 µg/kg ivermectin: results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia

Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 µg/kg ivermectin: results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia

Abstract Background After ivermectin became available, diethylcarbamazine (DEC) use was discontinued because of severe adverse reactions, including ocular reactions, in individuals with high Onchocerca volvulus microfilaridermia (microfilariae/mg skin, SmfD). Assuming long-term ivermectin use led to...

Full description

Bibliographic Details
Main Authors: Eric M. Kanza, Amos Nyathirombo, Jemmah P. Larbelee, Nicholas O. Opoku, Didier K. Bakajika, Hayford M. Howard, Germain L. Mambandu, Maurice M. Nigo, Deogratias Ucima Wonyarossi, Françoise Ngave, Kambale Kasonia Kennedy, Kambale Kataliko, Kpehe M. Bolay, Simon K. Attah, George Olipoh, Sampson Asare, Mupenzi Mumbere, Michel Vaillant, Christine M. Halleux, Annette C. Kuesel
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Parasites & Vectors
Subjects:
Onchocerciasis
Moxidectin
Ivermectin
Diethylcarbamazine
Ocular microfilariae
Microfilariae in the anterior chamber
Online Access:https://doi.org/10.1186/s13071-023-06087-3

Internet

https://doi.org/10.1186/s13071-023-06087-3

Similar Items